0000950170-24-077522.txt : 20240625
0000950170-24-077522.hdr.sgml : 20240625
20240625200030
ACCESSION NUMBER: 0000950170-24-077522
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240621
FILED AS OF DATE: 20240625
DATE AS OF CHANGE: 20240625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brown Ryan Edward
CENTRAL INDEX KEY: 0001848718
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 241070352
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: STE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
ownership.xml
4
X0508
4
2024-06-21
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001848718
Brown Ryan Edward
215 FIRST STREET
SUITE 415
CAMBRIDGE
MA
02124
false
true
false
false
EVP, General Counsel
true
Common Stock
2024-06-21
4
M
false
6250
A
34938.00
D
Common Stock
2024-06-24
4
F
false
2352
164.64
D
32586.00
D
Common Stock
2024-06-25
4
M
false
23500
62.77
A
56086.00
D
Common Stock
2024-06-25
4
S
false
7644
158.07
D
48442.00
D
Common Stock
2024-06-25
4
S
false
2200
159.14
D
46242.00
D
Common Stock
2024-06-25
4
S
false
975
160.31
D
45267.00
D
Common Stock
2024-06-25
4
S
false
4168
161.82
D
41099.00
D
Common Stock
2024-06-25
4
S
false
17581
162.65
D
23518.00
D
Common Stock
2024-06-25
4
S
false
3840
163.53
D
19678.00
D
Common Stock
2024-06-25
4
S
false
2549
164.52
D
17129.00
D
Performance Stock Units
2024-06-21
4
A
false
5500
0
A
Common Stock
5500
5500
D
Performance Stock Units
2024-06-21
4
A
false
6250
0
A
Common Stock
6250
6250
D
Performance Stock Units
2024-06-21
4
M
false
6250
0
D
Common Stock
6250
0
D
Stock Option (right to buy)
62.77
2024-06-25
4
M
false
23500
0
D
2019-02-28
2028-02-28
Common Stock
23500
0
D
Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.
Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.58 to $158.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.67 to $159.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.71 to $160.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.04 to $162.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.12 to $163.09, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.19 to $163.98 inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.
/s/ Ryan Brown
2024-06-25